Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force.
The International Society for Biological Therapy of Cancer (iSBTc, recently renamed the Society for Immunotherapy of Cancer, SITC) hosted a one-day symposium at the National Institutes of Health on September 30, 2010 to address development and application of biomarkers in cancer immunotherapy. The symposium, titled Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Task Force, gathered approximately 230 investigators equally from academia, industry and governmental/regulatory agencies from around the globe for panel discussions and presentations on the following topics: 1) immunologic monitoring: standardization and validation of assays; 2) correlation of immunity to biologic activity, clinical response and potency assays; 3) novel methodologies for assessing the immune landscape: clinical utility of novel technologies; and 4) recommendations on incorporation of biomarkers into the clinical arena. The presentations are summarized in this report; additional program information and slides are available online at the iSBTc/SITC website.
13 references, click to expand
-
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.J Clin Oncol. 2006 Dec 1;24(34):5373-80 PMID: 17135638
-
Effector memory T cells, early metastasis, and survival in colorectal cancer.N Engl J Med. 2005 Dec 22;353(25):2654-66 PMID: 16371631
-
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5 PMID: 17360651
-
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.Clin Cancer Res. 2011 May 15;17(10):3064-76 PMID: 21558394
-
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".J Transl Med. 2008 Dec 23;6:81 PMID: 19105846
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.N Engl J Med. 2010 Jul 29;363(5):411-22 PMID: 20818862
-
A model for harmonizing flow cytometry in clinical trials.Nat Immunol. 2010 Nov;11(11):975-8 PMID: 20959798
-
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.N Engl J Med. 2003 Jan 16;348(3):203-13 PMID: 12529460
-
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.Science. 2006 Sep 29;313(5795):1960-4 PMID: 17008531
-
Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival.Br J Cancer. 2006 Jan 30;94(2):239-46 PMID: 16404434
-
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.J Transl Med. 2009 Jun 17;7:45 PMID: 19534815
-
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 PMID: 16344461
-
AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development.Clin Cancer Res. 2010 Jul 1;16(13):3299-318 PMID: 20501613
Contact
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
WeChat Official Account
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: product@genelibs.com
Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2
